FSHD
Clinical trials for FSHD explained in plain language.
Never miss a new study
Get alerted when new FSHD trials appear
Sign up with your email to follow new studies for FSHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for FSHD: phase 3 trial of AOC 1020 begins
Disease control Recruiting nowThis study tests an experimental drug called AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 adults with a confirmed FSHD diagnosis who can still walk will receive either the drug or a placebo by I…
Matched conditions: FSHD
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 09:33 UTC
-
New registry aims to unlock FSHD mysteries through patient data
Knowledge-focused Recruiting nowThis study creates a registry for people with facioscapulohumeral muscular dystrophy (FSHD) to share their health experiences and data. Up to 5,000 participants in the U.S. will provide information on symptoms, progression, and quality of life. The goal is to help researchers bet…
Matched conditions: FSHD
Sponsor: FSHD Society • Aim: Knowledge-focused
Last updated May 19, 2026 11:47 UTC